Objective: Mediastinal nodal metastasis is related to poor prognosis in surgically resected non-small-cell lung cancer (NSCLC) and the prognosis becomes worse with an increasing number of nodal stations involved. However, intra-operative designation of each nodal station might be difficult and confusing because of the adjacency of the nodal stations, and this may cause inaccurate nodal staging. The new concept of a 'nodal zone' was proposed by the IASLC lung cancer staging project (IALC, International Association for the Study of Lung Cancer), and we investigated the impact of the 'nodal zone' on the survival of pathological N2 patients. Methods: From a total of 1186 patients with NSCLC, who underwent surgical resection with curative intent, we analysed the survival data of 217 patients with ipsilateral mediastinal metastasis retrospectively. Results: The operative mortality rate was 1.4% (three patients) and median follow-up period was 35.4 months. The 5-year overall survival rate was 36.5% (median: 39.3 months; confidence interval (CI): 32.05-46.62). Median disease-free survival was 17.4 months (CI: 13.84-21.03). Overall and disease-free survival were better in the single-zone metastasis group than in the multiple zone group (median: 48.5 vs 33.4 months, p = 0.001, CI: 32.05-46.62, and 20.4 vs 10.6 months, p < 0.001, CI: 13.84-21.03). Among those of the single nodal zone metastasis group, no differences were found between the single and multiple nodal station metastasis groups in overall and disease-free survival. Conclusions: Patients with single nodal zone metastasis showed favourable outcomes compared with the multiple zone metastasis group. Even though two or more nodal stations were involved, the outcome was favourable if the nodal stations involved were confined to a single nodal zone. In conclusion, patients with single nodal zone metastasis can benefit from surgical resection. #
Introduction
In case of stage I, II and a small group of IIIA non-small-cell lung cancer (NSCLC) without mediastinal metastasis, surgical resection and mediastinal lymph node dissection are the mainstay of treatment. However, the prognosis after surgical resection for NSCLC patients with mediastinal lymph node metastasis was poor and the majority of these patients experienced distant failure after surgery [1] . Some randomised studies have suggested that neo-adjuvant chemotherapy is recommended prior to surgery in stage IIIA patients with mediastinal lymph node metastases [2, 3] . Thereafter, it has been believed that NSCLC patients with ipsilateral mediastinal nodal metastasis could not benefit from surgical resection alone, and thus multimodal treatments, such as neo-adjuvant chemotherapy followed by surgery or chemoradiotherapy, have been introduced. Recent randomised studies have shown that multimodal treatment including surgery arm was not superior to that including radiation therapy [4, 5] . Current lung cancer treatment guidelines published by the National Comprehensive Cancer Network (NCCN) and American College of Chest Physicians (ACCP) excluded surgical resection from the initial treatment option in biopsy-proven stage IIIA NSCLC [6, 7] . However, N2 disease has a heterogeneous diversity: from single N2 metastasis or minimal N2 disease unsuspected preoperatively to bulky multi-station N2 disease. Recent reports have demonstrated that patients with some subgroups of N2 disease, such as single station N2 metastasis, microscopic metastasis and left upper lobe tumours with subaortic metastasis, have shown better survival than others after surgical resection. The extent of lymph node metastasis is well known as an important prognostic factor, and the prognosis becomes worse with an increasing number of involved nodal stations or lymph nodes [8] [9] [10] [11] [12] . However, intra-operative designation of each nodal station might be difficult and confusing because of the adjacency of the nodal stations, especially in the case of the right upper and lower paratracheal nodes. This may cause inaccurate nodal staging postoperatively. Recently, in the process of a new lung cancer staging project by the International Association for the Study of Lung Cancer (IASLC), the new concept of the 'nodal zone' was proposed as a new N descriptor [13, 14] . We investigated the impact of the 'nodal zone' on the survival of surgically resected pathological N2 patients.
Materials and methods

Materials
A total number of 1186 patients with NSCLC underwent surgical resection with curative intent at the National Cancer Center, South Korea, from April 2001 to December 2006, and we retrospectively reviewed the hospital records of 217 patients who had mediastinal metastasis on postoperative pathological examination. Preoperative work-up included chest X-ray, computed tomography (CT) scan of the chest, fibreoptic bronchoscopy, whole-body bone scintigraphy and brain magnetic resonance imaging (MRI). Integrated positron emission tomography scans (PET-CT) have been performed as part of routine staging work-up since 2006. Mediastinoscopy and endobronchial ultrasound-guided trans-bronchial needle aspiration (EBUS-TBNA) were carried out for selected patients. In a total of 1186 patients, complete surgical resection of the tumour was not successful in six patients (0.5%). Eighty-three patients (7.0%) received neo-adjuvant treatments, seven of the 83 patients received neo-adjuvant concurrent chemoradiation therapies and the other 76 patients received cisplatin-based neo-adjuvant chemotherapies. The number of patients who had ipsilateral mediastinal metastasis was 291. Fifty-seven patients were excluded from the study for neo-adjuvant therapies, five patients for lesser resections, three patients for palliative resections and nine patients for double primary cancer within 5 years preceding lung cancer surgery. Finally, 217 patients were enrolled in the study. Exclusion criteria were as follows: limited resections (wedge resection, segmentectomy, etc.), palliative resections, history of double primary cancers and history of neoadjuvant therapies. The local institutional review board approved this retrospective study.
Methods
Lymph nodes which were >1 cm in short diameter in a chest CT or showed a maximum standardised uptake value (SUV) of >2.5 in a PET-CT were considered to be metastatic nodes in the clinical staging. Mediastinoscopy, EBUS-TBNA or a PET scan was performed for selected patients with suspected N2 and N3 lesions. Patients with N3 lesions in the invasive staging were excluded from surgery and patients with N2 lesions underwent either surgical resections or neoadjuvant therapies. Patients with mediastinal lymph nodes >2 cm, or multi-stational or with extranodal invasion in CT or PET scan underwent neo-adjuvant therapies or definitive concurrent chemoradiation therapy with or without confirming tissue diagnosis through mediastinoscopy or TBNA. Surgical resections were performed by four thoracic surgeons through posterolateral thoracotomy incisions or videoassisted thoracic surgery (VATS). Anatomical resections (lobectomy, bilobectomy or pneumonectomy) and complete mediastinal lymph node dissections were performed in all patients. The lymph node classification of Mountain and Dressler was used during preoperative study, surgery and postoperative pathological reports [15] . The new concept of 'nodal zone', which was proposed by the IASLC lung cancer staging project to substitute for current N-stage descriptors, was used to analyse survival. Lymph node stations 1-4 of the Mountain and Dressler map were grouped into the upper zone, stations 5 and 6 into the Aortopulmonary zone and 8 and 9 into the lower zone, while station 7 was designated as the subcarinal zone [13, 14] . Adjuvant therapies and treatments after recurrences were administered according to local protocols.
The patients were followed up every 3 months for the first 2 years after surgery and every 6 months after that up to 5 years. Chest radiographs were obtained every 3 months and chest CT scans were obtained every 6 months. Brain MRI, PET-CT or bronchofibroscopy was performed for symptomatic patients during the follow-up period.
Statistical analysis
All statistical analyses were performed using STATA statistical software (version 10.1, Statacorp, TX, USA). The overall survival was defined as the time interval between surgery and death from any cause. Documented loco-regional and distant recurrences and deaths of any cause were used as events for disease-free survival. Survival rates were calculated by means of the Kaplan-Meier method, and the differences between subgroups were compared using the logrank test. Univariate analysis of the prognostic factors for survival was performed using the log-rank test and Cox's proportional hazard model, and multivariate analysis of the prognostic factors was performed by means of Cox's proportional hazard model. A statistically significant difference was defined as a p-value of <0.05.
Results
The mean age of the enrolled patients was 60.5 years, ranging from 25 to 84. The majority of the patients were male (170/217). Ninety-three patients (42.9%) were suspected of having clinical N0 or N1 disease and 114 (52.5%) patients of having clinical N2 disease. Ten patients who were suspected of having clinical N3 disease on a chest CT scan underwent either mediastinoscopic biopsy, EBUS-TBNA or a PET scan. Detailed characteristics of the 217 patients are listed in Table 1 .
Mediastinoscopies were performed in nine patients. Of 217 patients, 212 patients underwent anatomical resections and mediastinal lymph node dissections under standard posterolateral thoracotomy, and the other five patients received VATS. Lobectomies were performed in 142 patients (65.4%), bilobectomies in 32 (14.7%) and pneumonectomies in 43 (19.8%). Operative mortality occurred in three patients (1.4%).
Squamous cell carcinoma was the most common histology (108 patients, 49.8%) and 96 patients had adenocarcinomas. The mean number of mediastinal nodes resected for each patient was 24.1 (median: 23, standard deviation (SD): 8.9, range: 8-60).
Fifty percent of the patients did not receive any adjuvant treatments (108 patients, 49.8%). Adjuvant chemotherapy with cisplatin-based regimens was given to 71 patients (32.7%) and radiotherapy to 38 (17.5%). In the single nodal zone metastasis group, 87 of 153 patients (56.9%) did not receive any adjuvant therapies, 16 patients (10.5%) received adjuvant radiation therapies and 50 (32.7%) received adjuvant chemotherapies. On the other hand, in the multiple nodal zone metastasis group, 21 of 64 patients (32.8%) did not receive any adjuvant treatments, 22 patients (34.4%) received adjuvant radiation therapies and 21 (32.8%) received chemotherapies.
The median follow-up period was 35.4 months. Recurrences occurred in 127 patients (58.5%) during the follow-up period. Treatments after recurrence were given according to local protocols.
Pattern of nodal metastasis according to the zone
A total of 153 patients had single nodal zone metastasis, 49 patients had two-zone metastases and 15 patients had three-zone metastases. In patients of the single-zone metastasis group, the right upper lobe tumours mainly metastasised to the upper zone, left upper lobe tumours to the AP zone and both lower lobe tumours to the subcarinal zones (Table 2 ). When two-nodal zones were involved, rightsided tumours mainly metastasised to the upper and subcarinal zone and left upper tumours to the upper and AP zone. In cases of left lower lobe tumours, the subcarinal and lower zone frequently metastasised (Table 3) .
Analysis of survival
The overall 5-year survival rate was 36.5% (median: 39.3 months, CI: 32.05-46.62). Median disease-free survival was 17.4 months (CI: 13.84-21.03; Fig. 1 ). The overall and disease-free survival were significantly better in single nodal zone metastasis group compared with two-zone metastasis group ( p = 0.003 and p < 0.001). The overall and diseasefree survival of the two-nodal zone metastasis group and three-nodal zone group were similar ( p = 0.75 and 0.45), these two groups were grouped together and named the multiple-zone metastasis group. The survival curves were drawn according to the number of nodal zones involved for all patients (Fig. 2) . The overall survival was significantly better in the single-zone metastasis group than in multiple zone group (median: 48.5 vs 33.4 months, p = 0.001, CI: 32.05-46.62), and disease-free survival was also better in the single-zone metastasis group than in the multiple-zone group (median: 20.4 vs 10.6 months, p < 0.001, CI: 13.84-21.03).
The number of patients with single nodal zone metastasis was 153. Among these patients, 122 patients had only one nodal station metastasis, 28 patients had two-station metastasis and three patients had three-station metastasis. There were no statistically significant differences in overall survival and disease-free survival between the single and multiple nodal station metastasis groups (Fig. 3) . In the single nodal-zone metastasis group, 31 patients had multiple nodal station metastases. The zone that was involved of 23 out of 31 patients was the right upper zone and that of the other eight patients was the AP zone. The overall and disease-free survival was slightly better in the right upper zone, but the differences were not significant.
Adjuvant therapy
Fifty percent of the patients did not receive any adjuvant treatments (108, 49.9%). Adjuvant chemotherapy was given to 71 patients (32.7%) and radiotherapy to 38 (17.5%). Adjuvant chemotherapy was not a routine protocol for completely resected stage IIIA lung cancer in our institution prior to 2004; only seven (6.6%) patients received adjuvant chemotherapy and 72 of 106 patients did not receive any adjuvant treatments prior to 2004. Sixty-four of 111 (57.7%) patients received adjuvant chemotherapy after 2004. The overall survival rate of the adjuvant radiotherapy group was similar to that of the no-treatment group. The overall survival of the adjuvant chemotherapy group was better than the no-treatment group (median: 55.6 vs 25.5 months, p = 0.03, CI: 30-56.3), but disease-free survival was similar ( p = 0.15).
Pattern of recurrence
Recurrences occurred in 127 patients (58.5% of 217 patients) during the follow-up period. Seventeen patients had loco-regional recurrences only and 110 patients (86.6%) had distant failures with or without loco-regional recurrences. In single nodal zone metastasis group, 77 of 153 patients (50.3%) experienced recurrences and 50 of 64 patients (78.1%) in the multiple zone group. Distant failures were more common in the multiple-zone metastasis group (63/77 (81.8%) vs 47/50 (94.0%), p = 0.062). Treatments after recurrences included surgery for local and distant metastases (e.g., solitary brain or adrenal metastasis and palliative surgery for bone metastasis), palliative radiation and chemotherapy. Palliative chemotherapies were given to patients with distant metastasis according to local prospective trial protocols. Fifteen patients received conservative treatment only. Sixty-eight of 77 patients (88.4%) in the single nodal zone metastasis group and 44 of 50 patients (88.0%) in the multiple nodal zone metastasis group received treatments described above. There was no significant survival difference according to the pattern of recurrence. The overall survival was better in the patients treated with chemotherapy-based therapies than the non-chemotherapybased treatment group (median survival after recurrence: 22.2 vs 6.5 months, p < 0.001, CI: 13.8-23.3).
Prognostic factors
Univariate analysis for overall survival indicated that increasing age, male sex, pneumonectomy, increasing number of involved lymph nodal zones and no history of adjuvant chemotherapy were significantly associated with poor outcome. An increasing number of involved lymph nodal zones were significantly associated with poor disease-free survival (Table 4) . Age, sex, number of involved lymph nodal zones and adjuvant chemotherapy were revealed to be important prognostic factors affecting overall survival in multivariate analysis using the Cox regression method (Table 5 ).
Discussion
Although mediastinal metastasis in NSCLC is related to poor prognosis, single mediastinal nodal station metastasis in surgically resected NSCLC patients has been reported to have favourable outcomes [16, 17] . Cerfolio and Bryant showed that 5-year survival of patients with unsuspected N2 disease who underwent complete resection, followed by adjuvant therapy, was 35% and patients with single station N2 disease fare better [18] . On the other hand, Ohta et al. reported a 5-year survival rate of 27.1% in single level N2-disease NSCLC patients and suggested that initial operation had yet to be validated for patients with this disease [19] . Nevertheless, 5-year survival rates of non-surgery arms reported by some randomised studies range from 14% to 20% and did not exceed 30% [4, 5] . In fact, many surgeons dissect mediastinal lymph nodes in an en bloc fashion and intra-operative designation of each nodal station might be confusing and difficult. A discrepancy in intra-operative nodal designations between Western and Japanese surgeons was reported by Watanabe et al. [20] . Therefore, the new concept of 'nodal zone' was proposed by the IASLC lung cancer staging project in order to reconcile the Naruke and the MD-ATS lymph node maps [13] [14] [15] 21] . We investigated the impact of the 'nodal zone' on the survival of surgically resected pathological N2 patients.
In our series, the overall 5-year survival rate of resected N2 disease patients was 36.5%, and median survival was 39.3 months. In the survival analyses, according to the number of involved nodal zones for all patients, the overall survival and disease-free survival were significantly better in the singlezone metastasis group than in the multiple-zone group and the median overall survival of the single nodal zone metastasis group reached up to 48.5 months, whereas that of the multiple-zone group was only 33.4 months. In addition, there was no statistically significant survival difference between the single station metastasis group and multiple station metastasis group when only one nodal zone was involved. Although Rusch et al. did not accept the concept of 'nodal zone' as an N descriptor because of an insufficient number of patients for analyses [13, 14] , we think that the nodal zone could be used as an important prognostic factor which can show apparent survival differences in this particular group of patients.
The International Adjuvant Lung Cancer Trial (IALT) reported that the adjuvant chemotherapy after surgical resection of stage I-III patients resulted in better overall and disease-free survival and lesser loco-regional and distant failures than in controls [22] . The overall survival of the Table 4 Univariate analysis of prognostic factors for overall and disease-free survival.
Variables
Overall survival Disease-free survival adjuvant chemotherapy group in our study was better than the no-treatment group or radiation group, but disease-free survival was similar. This difference in overall survival might have resulted from the fact that young age and female sex were more common in the adjuvant chemotherapy group and the follow-up period was relatively shorter in this group of patients because adjuvant chemotherapy was not a routine protocol for surgically resected N2-disease patients prior to 2004. There are some disagreements about the effects of subcarinal nodal station involvement on survival; some authors have argued that the presence of subcarinal nodal metastasis is related to worse prognosis [23] , and others have argued that there are no differences in survival based on the presence of subcarinal node metastasis [24, 25] . In our study, overall survival of patients with subcarinal metastasis was worse ( p = 0.055), but we could not find any survival differences according to subcarinal involvement in the single-station, single-zone metastasis or two-zone metastasis groups ( p = 0.52, 0.370 and 0.454). We concluded that the survival difference was attributed to more multiple-zone metastasis patients in the subcarinal metastasis group.
Tumour histology did not affect overall and disease-free survival ( p = 0.54, 0.538). However, the survival difference between single-and multiple-zone metastasis varied greatly according to histology. The overall and disease-free survival were better in the single-zone group with squamous cell carcinomas ( p < 0.001 and p < 0.001). Overall survival of the single-zone metastasis group was not superior to that of the multiple-zone group with adenocarcinomas ( p = 0.23), but disease-free survival was significantly better in the singlezone group with adenocarcinomas ( p = 0.001).
This study is a retrospective study based on postoperative pathology reports. Although we showed single-zone metastasis in N2-positive NSCLC patients to have more favourable outcomes than the other varieties, we do not have a perfect method for accurately diagnosing the status of mediastinal node metastasis preoperatively. However, the current practice of excluding patients with single N2 metastasis from surgery as an initial treatment option might need to be reconsidered.
Conclusions
Patients with single nodal zone metastasis showed favourable outcomes compared with the multiple-zone metastasis group. Even though two or more nodal stations were involved, the outcome was favourable if the nodal stations involved were confined to a single nodal zone. Primary surgery followed by adjuvant chemotherapy could be another treatment option for single-zone N2-positive NSCLC patients. Further prospective randomised studies will be needed for this particular group of patients.
